| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $209,312,376 ) (Continued on the next page) |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01HL169015 | Enhancing cardiovascular risk prediction in HIV using novel factors in the REPRIEVE trial | 000 | 3 | NIH | 5/12/2026 | $698,245 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R33MH132869 | Suicide Circuit Therapeutics: Engaging Novel Targets with Rapid and Individualized MRI-Guided Accelerated TMS | 000 | 3 | NIH | 5/11/2026 | $867,497 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | F32HL176201 | Dissecting the functions of muscarinic receptor subtypes in the airway epithelium for asthmatic allergen uptake, inflammation, and remodeling | 001 | 2 | NIH | 5/8/2026 | $1,308 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01CA262874 | Mechanisms of APOBEC3A-induced cancer evolution and cancer vulnerability | 000 | 3 | NIH | 4/9/2026 | $530,113 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01EB028782 | Genetic-engineered control of the immunogeneic state of vascular composite allografts during preservation | 000 | 6 | NIH | 4/9/2026 | $610,988 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01AR082825 | Development of engineered fasciocutaneous skin flaps | 000 | 4 | NIH | 4/9/2026 | $330,660 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R35GM158046 | Revealing the crosstalk between one carbon metabolism, SAM availability and chromatin methylation | 000 | 2 | NIH | 5/12/2026 | $453,750 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01DK146964 | GPAT2 REGULATES MINERAL METABOLISM IN KIDNEY DISEASE | 000 | 1 | NIH | 4/8/2026 | $622,959 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01MH136276 | Targeting Emotion Regulation in Bipolar Disorder with Intermittent Theta Burst Stimulation: A Mechanistic Study | 000 | 3 | NIH | 5/5/2026 | $824,334 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01DA054145 | Characterizing Proximal Risk for Depressive Symptoms and Suicidal Ideation with Acute Cannabis Use and Withdrawal Among Adolescents Using Ecological Momentary Assessment | 000 | 3 | NIH | 3/31/2026 | $763,679 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01NS126420 | Somatic Repeat Expansions as a Therapeutic Target for Trinucleotide Repeat Disorders | 000 | 5 | NIH | 4/9/2026 | $412,058 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | P41EB015903 | Center for Biomedical OCT Research and Translation | 000 | 15 | NIH | 3/31/2026 | $1,259,558 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R35NS116852 | Neuronal Ion and Volume Shifts After Acute Brain Injury | 000 | 7 | NIH | 4/9/2026 | $1,226,000 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01CA290785 | Novel regulation and functions of TEAD-VGLL complex | 000 | 2 | NIH | 4/27/2026 | $664,344 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | P50DC015446 | Clinical Research Center for the Improved Prevention, Diagnosis, and Treatment of Vocal Hyperfunction | 001 | 9 | NIH | 4/27/2026 | $66,941 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | K99AR084551 | Non-canonical transcriptional activation of MITF in pigment cells. | 000 | 1 | NIH | 4/8/2026 | $107,784 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01HL166342 | Indexed Exercise Blood Pressure and Its Relationship with Adverse Vascular and Ventricular Remodeling | 000 | 1 | NIH | 5/4/2026 | $614,843 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01AG082223 | Identifying microscopic vasculature within entorhinal cortex in healthy aging and its proximity to pathology profiles in Alzheimer's disease | 000 | 2 | NIH | 3/30/2026 | $699,509 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R21CA290650 | Reconstituting human testicular germ cell neoplasia in situ (GCNIS) in vitro using iPSC-derived primordial germ cell-like cells (PGCLCs) and genetically engineered human testicular cancer cells | 000 | 2 | NIH | 5/5/2026 | $192,844 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01HD109436 | Continuous longitudinal atlas construction for the study of brain development | 000 | 4 | NIH | 4/28/2026 | $647,033 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R21DA064871 | Next generation PET neuroimaging for safe, accessible measurement of opioid addiction neurobiology | 000 | 1 | NIH | 5/5/2026 | $451,670 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01AG079142 | Building predictive algorithms to identify resilience and resistance to Alzheimer's disease | 000 | 4 | NIH | 4/17/2026 | $982,110 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01NS124679 | Preventing and Reversing Mitochondrial Leigh Syndrome with Hypoxia | 001 | 5 | NIH | 3/18/2026 | $49,611 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | K23DK135798 | REACH-Es: Adapting a digital health tool to improve diabetes medication adherence among Latino adults | 000 | 4 | NIH | 3/19/2026 | $195,907 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | K23HD110597 | Resilient Families (R-FAM): A dyadic resiliency intervention for parents of babies in neonatal intensive care | 000 | 4 | NIH | 3/19/2026 | $169,204 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01CA276116 | Mechanisms of aggressive Rhabdomyosarcoma. | 001 | 4 | NIH | 4/16/2026 | $54,000 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01CA289485 | Analyzing DNA replication and damage vulnerability in IDH mutant glioma | 000 | 3 | NIH | 3/19/2026 | $401,140 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01NS131395 | Toward Personalized Prognosis and Outcomes in Primary Progressive Aphasia | 000 | 2 | NIH | 4/17/2026 | $823,683 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | UM1AI144295 | Targeting T cell Subsets in Autoimmune Disease | 000 | 8 | NIH | 4/29/2026 | $333,918 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01AR081344 | Rapid Three-dimensional Simultaneous Knee Multi-Relaxation Mapping | 000 | 5 | NIH | 4/27/2026 | $369,383 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | P50DC015446 | Clinical Research Center for the Improved Prevention, Diagnosis, and Treatment of Vocal Hyperfunction | 002 | 9 | NIH | 4/28/2026 | $154,774 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01DK131543 | Normothermic perfusion of steatotic livers for transplantation | 000 | 3 | NIH | 5/7/2026 | $268,000 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01CA293063 | Pancreatic cancer patient-derived xenograft tumors for translational studies in precision cancer medicine | 000 | 2 | NIH | 3/30/2026 | $654,197 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01NS127808 | Local Skull Marrow Sensing and Response to CNS Inflammation | 000 | 5 | NIH | 4/27/2026 | $682,220 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R35GM157035 | Integrating frequency and phenotypic association data to improve interpretation of rare genetic variants | 000 | 2 | NIH | 5/7/2026 | $412,500 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | K01DK133637 | Improved detection of gene-diet interactions via longitudinal data, metabolomic proxies, and polygenic scores | 000 | 5 | NIH | 4/6/2026 | $146,880 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01AG081195 | BET-BD1 Selective Neuroimaging probes for Alzheimer's disease research | 000 | 2 | NIH | 4/7/2026 | $804,605 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01AG075899 | Addressing the chronic pain-early cognitive decline comorbidity among older adults; The Active Brains study | 000 | 5 | NIH | 4/17/2026 | $594,666 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | K23AT013273 | Toolkit for Optimal Pain Management in the Emergency Department: A mind-body intervention for pain catastrophizing and pain anxiety among individuals with chronic pain in the Emergency Department | 000 | 1 | NIH | 4/17/2026 | $170,640 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | K99CA296772 | Elucidating Thiol Reductive Stress in Lung Cancer Growth and Metastasis | 001 | 2 | NIH | 4/16/2026 | $14,013 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | K01DK146206 | c-Kit receptor signaling in the modulation of collecting duct function | 000 | 1 | NIH | 3/19/2026 | $110,865 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01CA299969 | Defining the genomic and biologic impact of LINE-1 activity in fallopian tube epithelial cells | 000 | 2 | NIH | 4/24/2026 | $712,073 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01CA285582 | Investigating CREB5-driven mechanisms of immune therapy resistance | 001 | 2 | NIH | 4/16/2026 | $61,047 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R61CA297878 | Streamlining sample preparation with high throughput SpinEx (Separation processing integration for Extracellular vesicles) | 001 | 2 | NIH | 4/16/2026 | $23,142 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01DE031261 | Integration of polygenic risk and facial morphometrics to decipher the genetic susceptibility of orofacial clefting | 001 | 5 | NIH | 4/15/2026 | $75,503 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R13DA064375 | Joint Meeting on Youth Prevention, Treatment, and Recovery | 000 | 1 | NIH | 4/17/2026 | $24,980 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01CA260890 | Synergistic combinatorial DNA damage response/repair inhibition and Sacituzumab Govitecan in triple-negative breast cancer | 001 | 5 | NIH | 4/17/2026 | $55,978 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01NS117609 | Human genetics and molecular mechanisms of Vein of Galen aneurysmal malformation | 001 | 6 | NIH | 4/17/2026 | $678,120 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01CA248923 | Subclonal heterogeneity and outcome disparities in Triple-Negative Breast Cancer among African Americans | 000 | 5 | NIH | 3/19/2026 | $784,127 |
|
